Literature DB >> 11352857

Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.

W F Lawrence1, B N Peshkin, W Liang, C Isaacs, C Lerman, J S Mandelblatt.   

Abstract

Counseling and predictive testing are now available for the recently isolated BRCA1 and BRCA2 breast cancer susceptibility genes. We examined the societal costs of providing this counseling and testing to women at risk of having a breast cancer susceptibility mutation. Genetic counselors in a research program prospectively monitored the time necessary to provide counseling and results disclosure. A time-motion study was used to determine time spent on phone calls, preparation, and documentation for counseling. Study participants were surveyed to determine travel time and need for dependent care during counseling. The test cost was calculated using the charge for full BRCA1/2 gene sequencing (Myriad Genetics, Inc.) multiplied by a Medicare-based cost-to-charge ratio. Counselors spent an average of 4.2 h providing genetic counseling for women at risk of having a susceptibility mutation. Genetic counseling without testing cost on average $213, whereas counseling, testing, and disclosure of results totaled $2057. A brief physician-based counseling instead of genetic counselor-based counseling would produce only small reductions in total costs. Providing counseling and testing to the study population averaged $8034 per mutation found. The cost of testing and counseling exceeded $2000. The counseling portion of the cost comprised only 16% of the total cost, with the remainder representing costs associated with testing; thus, alternatives to full genetic counseling that shorten counseling time are unlikely to have a large impact on the overall cost of counseling and testing. The cost of detecting a mutation within a population of women is highly dependent on the prevalence of the mutation in the population.

Entities:  

Mesh:

Year:  2001        PMID: 11352857

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

1.  Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.

Authors:  Victor R Grann; Priya R Patel; Judith S Jacobson; Ellen Warner; Daniel F Heitjan; Maxine Ashby-Thompson; Dawn L Hershman; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-07-20       Impact factor: 4.872

Review 2.  How to establish a high-risk cancer genetics clinic: limitations and successes.

Authors:  Mary B Daly; Beth Stearman; Agnes Masny; Elaine Sein; Susan Mazzoni
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

3.  Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.

Authors:  Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt; Yaojen Chang; Aimee M Near; Karin M Butler; Amanda Hoeffken; Sandra L Edwards; Antoinette M Stroup; Wendy Kohlmann; Amanda Gammon; Saundra S Buys; Marc D Schwartz; Beth N Peshkin; Anita Y Kinney; Jeanne S Mandelblatt
Journal:  J Oncol Pract       Date:  2016-01       Impact factor: 3.840

4.  Retinoblastoma: genetic testing versus conventional clinical screening in India.

Authors:  Biju Joseph; Mahesh Palanivelu Shanmugam; Madhuravasal Krishnan Srinivasan; Govindasamy Kumaramanickavel
Journal:  Mol Diagn       Date:  2004

Review 5.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

Review 6.  Hereditary breast cancer in Jews.

Authors:  Wendy S Rubinstein
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

Review 7.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

8.  Patient time requirements for anticoagulation therapy with warfarin.

Authors:  Daniel E Jonas; Betsy Bryant Shilliday; W Russell Laundon; Michael Pignone
Journal:  Med Decis Making       Date:  2009-09-22       Impact factor: 2.583

9.  Evaluation of group genetic counseling for hereditary breast and ovarian cancer.

Authors:  Yolanda Ridge; Karen Panabaker; Mary McCullum; Cheryl Portigal-Todd; Jenna Scott; Barbara McGillivray
Journal:  J Genet Couns       Date:  2009-01-06       Impact factor: 2.537

10.  Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings.

Authors:  Kathleen R Blazer; Bita Nehoray; Ilana Solomon; Mariana Niell-Swiller; Julie O Culver; Gwen C Uman; Jeffrey N Weitzel
Journal:  Genet Test Mol Biomarkers       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.